睿知中国疾病研究地图
候选清单0

即将招募食管鳞状细胞癌未注明分期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

Standardized MRI and Structured Reporting for Esophageal Squamous Cell Carcinoma

ClinicalTrials.gov 上登记的一项食管鳞状细胞癌开放试验,由郑州大学第一附属医院牵头,本站收录的另外 5 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月8日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

列出这项试验的中国大陆医院 6

登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。

  1. 牵头方郑州大学第一附属医院First Affiliated Hospital of Zhengzhou University郑州医院页面
  2. 研究中心复旦大学附属肿瘤医院Fudan University Shanghai Cancer Center上海医院页面
  3. 研究中心中山大学肿瘤防治中心Sun Yat-sen University Cancer Center广州医院页面
  4. 研究中心天津医科大学肿瘤医院Tianjin Medical University Cancer Institute & Hospital天津医院页面
  5. 研究中心四川大学华西医院West China Hospital成都医院页面
  6. 研究中心云南省肿瘤医院Yunnan Cancer Hospital昆明医院页面

登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心

来源:ClinicalTrials.gov 登记记录 NCT07769658,读取于 2026年11月8日;医院名称与本站医院名单匹配。 名称如何匹配

这项试验的核对清单 5

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(5 项)收起清单
  1. 18 岁 至 80 岁;性别:不限

    登记记录的入选字段

  2. Histologically confirmed esophageal squamous cell carcinoma based on endoscopic biopsy or other tissue examination

    入选标准第 2 条

    For Cohort A: no chemotherapy, radiotherapy, immunotherapy, targeted therapy, or other antitumor treatment before MRI; surgery planned within 14 days after MRI; and postoperative pathological T stage expected to be available

    入选标准第 7 条

    For Cohort B: neoadjuvant treatment followed by surgery selected by the clinical multidisciplinary team; baseline MRI completed within 14 days before neoadjuvant treatment; post-treatment MRI completed within 14 days before surgery; and pathological tumor regression grade of the primary tumor bed expected to be available

    入选标准第 8 条

  3. Definite distant metastasis, unresectable T4b disease, or another reason that prevents acquisition of a surgical pathological reference standard

    排除标准第 3 条

    Inadequate surgical specimen sampling or inability to determine pathological T stage or pathological tumor regression grade

    排除标准第 8 条

  4. Substantial disease progression, emergency intervention, or off-protocol treatment between MRI and surgery that prevents valid imaging-pathology comparison

    排除标准第 7 条

  5. Cervical esophageal cancer, a gastric primary tumor extending into the esophagus, or multiple primary lesions that prevent reliable imaging-pathology matching

    排除标准第 2 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:既往治疗;日常活动能力;化验:血常规、肝肾功能;怀孕、哺乳与避孕。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT07769658,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. Age 18 to 80 years, inclusive
  2. Histologically confirmed esophageal squamous cell carcinoma based on endoscopic biopsy or other tissue examination
  3. Primary tumor located in the thoracic esophagus
  4. Planned curative esophagectomy
  5. Able to complete the required esophageal MRI examination with diagnostically adequate image quality
  6. Able and willing to provide written informed consent
  7. For Cohort A: no chemotherapy, radiotherapy, immunotherapy, targeted therapy, or other antitumor treatment before MRI; surgery planned within 14 days after MRI; and postoperative pathological T stage expected to be available
  8. For Cohort B: neoadjuvant treatment followed by surgery selected by the clinical multidisciplinary team; baseline MRI completed within 14 days before neoadjuvant treatment; post-treatment MRI completed within 14 days before surgery; and pathological tumor regression grade of the primary tumor bed expected to be available

排除标准:Exclusion Criteria:

  1. Adenocarcinoma, neuroendocrine carcinoma, adenosquamous carcinoma, or another non-squamous histological type
  2. Cervical esophageal cancer, a gastric primary tumor extending into the esophagus, or multiple primary lesions that prevent reliable imaging-pathology matching
  3. Definite distant metastasis, unresectable T4b disease, or another reason that prevents acquisition of a surgical pathological reference standard
  4. Previous esophageal cancer surgery, radiotherapy, or another treatment that substantially altered local esophageal anatomy
  5. Contraindication to MRI, or contraindication to the gadolinium-based contrast agent when the required contrast-enhanced sequences cannot be completed
  6. Severe claustrophobia, inability to follow breathing instructions, or another cause of nondiagnostic image quality that persists after a safe repeat examination
  7. Substantial disease progression, emergency intervention, or off-protocol treatment between MRI and surgery that prevents valid imaging-pathology comparison
  8. Inadequate surgical specimen sampling or inability to determine pathological T stage or pathological tumor regression grade

引自 ClinicalTrials.gov, NCT07769658, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT07769658,读取于 2026年11月8日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT07769658